November 18, 2022 News by Patricia Valerio, PhD NervGen Completes Dosing Another Group With MS Candidate NVG-291 Dosing of NVG-291, NervGen Pharmaās investigational therapy for multiple sclerosis (MS) and other nervous system diseases, was completed in the third and final group of healthy postmenopausal women in a Phase 1 clinical trial. āCompleting the dosing of the final [group] of postmenopausal females in the MAD [multiple…
May 13, 2022 News by Lindsey Shapiro, PhD NervGen Cleared to Enroll Final Group in Trial of NVG-291 NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an investigational treatment for multiple sclerosis (MS) and other nervous system diseases. A safety review committee cleared the…
April 8, 2022 News by Marisa Wexler, MS #AAN2022 ā Phase 1 Data Shows NVG-291 Safe; Trial in MS Patients Anticipated NVG-291, an experimental therapy designed to promote nervous system repair, has so far been well tolerated in an ongoing Phase 1 study with healthy volunteers. “The Phase 1 study is progressing very well, and we are encouraged by the data we are seeing so far,” Daniel Mikol, MD, PhD, chief…
March 21, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: SPMS Transition, NVG-291, PIPE-307, Foralumab MS Doctors, Nurses in UK Struggle With Marking Transition to SPMS The issue highlighted in this story isn’t just a problem in the U.K.; it’s a universal MS problem. People with MS often ask how they will know when their illness has transitioned from relapsing to progressive. I respond…
March 17, 2022 News by Patricia Inacio, PhD NervGen Cleared to Enroll 2nd MAD Group in NVG-291 Trial NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion of its Phase 1 clinical trial of NVG-291, a therapeutic candidate for multiple sclerosis (MS). The trial’s Safety Review Committee approved the second group after seeing promising safety data…
January 3, 2022 News by Patricia Inacio, PhD Ascending Dosing Will Start in Trial of NVG-291 in Healthy Volunteers NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions, in a Phase 1 trial with healthy volunteers. This multiple ascending dose (MAD) part, in which participants will receive increasing doses of NVG-291…
November 15, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: NVG-291, Ocrevus, Tolebrutinib, Tecfidera Nerve Repair Therapy NVG-291 Safe, Well-tolerated in Healthy People This experimental therapy has a long way to go before it becomes reality. But it’s encouraging that this first step found NVG-291’s side effects to be mild and short-lasting. NVG-291 is designed to promote remyelination by modulating an enzyme called…
November 5, 2021 News by Steve Bryson, PhD Nerve Repair Therapy NVG-291 Safe, Well-tolerated in Healthy People A single dose of NVG-291, a potential nerve repair therapy for multiple sclerosis (MS), was safe and well-tolerated among healthy volunteers in a Phase 1 safety trial, and was found to have favorable pharmacological properties, new data show. Given the positive results thus far, a safety committee supervising…
September 29, 2021 News by Patricia Inacio, PhD NervGen Brings Advanced Imaging to Planned NVG-291 Trials A partnership will allowĀ NervGen to use Imeka‘s proprietary biomarker imaging technology to precisely measure changes in the brain and spinal cord in its upcoming clinical trials, including a study ofĀ NVG-291 in people with multiple sclerosis (MS) NervGen plans to initiate Phase 1b/2Ā trials intoĀ its lead candidate for neural…
August 23, 2021 News by Marta Figueiredo, PhD Top-line Data on NVG-291 in Healthy Volunteers Expected This Year NervGen Pharma announced that its Phase 1 clinical trial evaluating the safety and pharmacological properties of NVG-291 ā its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions ā in healthy volunteers is going according to plan, with early top-line data expected later this year. āThe…
July 19, 2021 News by Marisa Wexler, MS NervGen Sets Advisory Board to Support Upcoming NVG-291 Trial NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who will work with the company as it prepares to start a Phase 2 clinical trial next year testing its lead compound, NVG-291, in people with MS. “We are honored to…
September 10, 2019 News by Joana Carvalho, PhD NervGen Planning Clinical Trials of NVG-291, Peptide That Might Promote Myelin Repair NervGen PharmaĀ announced plans to open clinical trials evaluating the potential of its lead candidate NVG-291 to treat multiple sclerosis (MS) and spinal cord injury. NVG-291 is an investigational peptide that has shown an ability to stimulate nerve regeneration following an injury in several animal models of disease.
July 16, 2019 News by Marisa Wexler, MS Independent Mouse Study Reinforces Remyelinating Potential of ISP Therapy A new study demonstrates that intracellular sigma peptide (ISP) can promote remyelination in a mouse model of multiple sclerosis (MS). Importantly, this study was independent of NervGen, a pharmaceutical company that is developing an ISP-like compound āĀ NVG-291Ā ā for the treatment of nerve injury and MS. The study,…
July 3, 2019 News by Ana Pena PhD NervGen to Advance NVG-291 as Potential Remyelination Therapy for MS NervGen wants to advance the development of NVG-291, its lead investigational therapy for spinal cord damage, as a potential remyelination treatment for multiple sclerosis (MS), the company announced. Following preclinical data showing that NVG-291 promotes myelin repair and regeneration of damaged nerves in animal models of…